Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
Jazz Pharmaceuticals (JAZZ) will report its third-quarter 2026 financial results on November 2, 2026, after U.S. financial markets close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Jazz Pharmaceuticals (JAZZ) will report its third-quarter 2026 financial results on November 2, 2026, after U.S. financial markets close. Management will host a 4:30 p.m. ET webcast to discuss the results and provide a business and financial update. A replay will be available through the company’s investor website.
Key Figures
- Results report date
- November 2, 2026
- 2026 third-quarter financial results scheduled after market close
AI-generated analysis. How Rhea-AI works. Not financial advice.
Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Contacts:
Investors:
InvestorInfo@jazzpharma.com
Ireland +353 1 634 7800
U.S. +1 650 496 2717
Media:
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-third-quarter-financial-results-on-november-2-2026-302913000.html
SOURCE Jazz Pharmaceuticals plc